NCT05940441View on ClinicalTrials.gov

A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2027

Conditions

to Explore Whether the Adjuvant Therapy of Metronomic Capecitabine Could Improve the Disease-free Survival of Locoregionally Advanced Hypopharyngeal Carcinoma

Interventions

DRUG

Capecitabine 500Mg Oral Tablet

650 mg/m² body surface area twice daily for 1 year

Trial Locations (1)

Unknown

RECRUITING

Eye & ENT Hospital, Fudan University, Shanghai

All Listed Sponsors

lead

Eye & ENT Hospital of Fudan University

OTHER